Manuel Stingelin has a strong work experience history, starting in 2007 as a Credit Analyst at Huntsman and then moving on to roles such as Financial Accountant/Controller at Klöckner Pentaplast and Head of Finance & Controlling at Natco AG. In 2011, they joined Bristol Myers Squibb, where they held various positions, including Senior Accountant, Cost Accounting Manager, and Finance Lead/Associate Director. Their most recent role at Bristol Myers Squibb was as a Finance Associate Director, focusing on Cell Therapy Launch Readiness. In 2022, Manuel joined Vir Biotechnology as the Director of Financial Planning and Analysis for Tech Ops/Clinical, and in 2023, they transitioned into the role of Director of Corporate FP&A.
Manuel Stingelin has a diverse education history. Manuel obtained a Bachelor of Business Administration (BBA) from the University of Applied Sciences and Arts Northwestern Switzerland FHNW in 2008. In 2010, they pursued further education and completed a Master of Advanced Studies (MAS) in Corporate Finance from Lucerne University of Applied Sciences and Arts. Later, they attended the University of Toronto - Rotman School of Management from 2015 to 2017, where they earned a Master of Business Administration (MBA) degree. Manuel Stingelin also holds a Certified Public Accountant (CPA) certification from the State of Washington.
March 1, 2024 - present
June, 2023
April, 2022